The PKB/AKT pathway in cancer.more suppliers
In PLoS ONE, 2009
... 1∶80 (Novocastra, NCL-CBE-356); HER3 (clone RTJ1), 1∶100 (Novocastra, NCL-c-erbB-3); HER4 (clone sc-283), 1∶500 (Santa Cruz, ErbB-4); Akt1 (clone 2H10), 1∶500 (Cell Signaling, 2967); phospho-Akt (pAkt, Ser473), ...
HER3/ErbB3, an emerging cancer therapeutic target.
Houston, United States. In Acta Biochim Biophys Sin (shanghai), Jan 2016
HER3 is a member of the HER (EGFR/ErbB) receptor family consisting of four closely related type 1 transmembrane receptors (EGFR, HER2, HER3, and HER4).
Exercise for the heart: signaling pathways.
Nanjing, China. In Oncotarget, Sep 2015
The cellular adaptations associated with exercise are due to the activation of several signaling pathways, in particular, the growth factor neuregulin1 (NRG1)-ErbB4-C/EBPβ and insulin-like growth factor (IGF)-1-PI3k-Akt signaling pathways.
Genomic classification of lung cancer: toward a personalized treatment.
In Tunis Med, Jun 2015
Upon binding to its ligands, EGFRforms homodimers or heterodimers with other family members(ERBB2, ERBB3 or ERBB4),which inactivate intrinsic receptor tyrosine kinase activity and trigger a phosphorylation cascade of specific tyrosine residues within their cytoplasmicregulatory domains(3).
ErbB4 in Laminated Brain Structures: A Neurodevelopmental Approach to Schizophrenia.
Los Angeles, United States. In Front Cell Neurosci, 2014
I have used the ErbB4(-/-) HER4(heart) KO mice to study the neurodevelopmental insults associated to deficiencies in the NRG1-ErbB4 signaling pathway and their potential implication with brain disorders such as schizophrenia, a chronic psychiatric disease affecting 1% of the population worldwide.
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
Budapest, Hungary. In Curr Cancer Drug Targets, 2014
These include HER2 amplification, impaired access to the binding site (p95HER2, Δ16HER-2, MUC4), augmented signaling through other ERBB family receptors (HER1, HER3, HER4) and their ligands, activation of HER2 targets by alternate heterodimers (EphA2, IGF-1R, GDF15, MUC1*), signaling triggered by downstream members (PIK3CA, PTEN, SRC, mTOR), altered expression of cell cycle and apoptotic regulators (CDKs, p27(kip1), Bcl-2), hormone receptor status, resistance to antibody-dependent cellular cytotoxicity (FcγR), and altered miRNA expression signatures.
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
More papers using
Atlanta, United States. In J Clin Oncol, 2012
PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).